Setmelanotide acetate (RM-493; IRC-022493; BIM-22493; Imcivree), the acetate salt of Setmelanotide, is a peptide-based agonist of melanocortin 4 receptor (MC4R) approved in 2020 for the treatment of genetic obesity. It activates melanocortin 4 receptor (MC4R) with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively.

纯度：≥98%

CAS：1504602-49-6